Harry J Iland

7PUBLICATIONS
32CO-AUTHORS
Medical infection agents (incl. prions)Haematological tumoursInstruments and techniquesSynchrotrons and accelerators not elsewhere classifiedHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 17, 2025
Measurable residual disease intervention in AML: a new therapeutic horizon.

Andrew H Wei, Harry J Iland, Courtney D DiNardo

|Aug 18, 2025
APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy.

Harry J Iland

|Jan 28, 2025
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Harry J Iland, John Reynolds, Alan V Boddy

|Jan 09, 2025
In APL, 2 targets are better than 1!

Harry J Iland

|Aug 30, 2023
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.

Sun Loo, Andrew W Roberts, Natasha S Anstee

|Sep 08, 2022
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.

Harry J Iland, Nigel Russell, Richard Dillon

Pageof 2

Frequent Collaborators

4 joint publications

Andrew Wei

4 joint publications

John Reynolds

2 joint publications

Steven W Lane

1 joint publications

Zachary D Epstein-Peterson